

31 May 2007

SONIC HEALTHCARE ACQUIRES THE MEDICA LABORATORY GROUP IN SWITZERLAND

Sonic Healthcare Limited ("Sonic") (SHL.AX) is pleased to announce that it has acquired 100% of the Medica Laboratory Group ("Medica") based in Zurich, Switzerland.

Medica has a well-established position in the Swiss laboratory market and is led by Dr Franz Kaeppeli, who has been the driving force of the group for the past 30 years and who will continue in his role as CEO. The Medica Group has annual revenue of approximately Swiss Francs (CHF) 55 million.

The unique strengths of the Medica Group include:

- A long tradition of providing personalised laboratory service.
- Service provision throughout most of Switzerland.
- A leading position in scientific endeavours (national and international research projects and scientific publications).

The purchase price of the practice was ~CHF 98 million. The acquisition was debt funded and will be immediately earnings per share accretive.

Sonic Healthcare's CEO and Managing Director Dr Colin Goldschmidt said: "The acquisition of Medica represents an important addition to our expanding laboratory operations in Western Europe. Medica provides Sonic with an excellent base upon which to grow in the Swiss market and presents new opportunities for synergy capture within our evolving European federation of practices. Dr Kaeppeli and his experienced team of managers will continue to lead and operate the business into the future and we take this opportunity to warmly welcome all Medica staff to the Sonic team".

Dr Kaeppeli, CEO of Medica said: "This alliance provides an opportunity for Medica scientists to expand their valuable research in the fields of laboratory diagnostics and applied sciences on a broader, global scale. We feel privileged to continue to provide our personalised laboratory service within a dynamic, internationally renowned group such as Sonic Healthcare and believe that this partnership will create new opportunities for our customers as well as for our staff."

For further information regarding this announcement please contact:

Dr Colin Goldschmidt

Managing Director

Telephone: (02) 9855 5333 Facsimile: (02) 9878 5066 Email: colgold@msn.com.au